What Companies Are In The VanEck Semiconductor ETF?
There’s a lot to love about the VanEck Semiconductor ETF,…
Sell
25
ACHV Quote, Financials, Valuation and Earnings
Last price:
$3.68
Seasonality move
:
17.74%
Day range:
$3.64 - $3.77
52-week range:
$3.42 - $5.59
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
4.06x
Volume:
178.4K
Avg. volume:
139.8K
1-year change:
-11.27%
Market cap:
$127.2M
Revenue:
--
EPS (TTM):
-$1.11
Analysts' Opinion
-
Consensus RatingAchieve Life Sciences has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $16.44, Achieve Life Sciences has an estimated upside of 344.44% from its current price of $3.70.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $10.00 representing 100% downside risk from its current price of $3.70.
Fair Value
-
According to the consensus of 7 analysts, Achieve Life Sciences has 344.44% upside to fair value with a price target of $16.44 per share.
ACHV vs. S&P 500
-
Over the past 5 trading days, Achieve Life Sciences has underperformed the S&P 500 by -2.17% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Achieve Life Sciences does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Achieve Life Sciences revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Achieve Life Sciences reported revenues of --.
Earnings Growth
-
Achieve Life Sciences earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Achieve Life Sciences reported earnings per share of -$0.36.
Enterprise value:
94.2M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-3.77x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$37.1M | -$33.7M | -$31.3M | -$6.6M | -$12.5M | |
| EBITDA | -$36.8M | -$32.7M | -$29.9M | -$6.3M | -$12.1M | |
| Diluted EPS | -$3.99 | -$2.10 | -$1.11 | -$0.34 | -$0.36 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $24.1M | $34.7M | $21M | $21.9M | $45.5M | |
| Total Assets | $27.6M | $37.8M | $23.7M | $24.3M | $47.9M | |
| Current Liabilities | $1.8M | $3.1M | $6.9M | $4.1M | $6.7M | |
| Total Liabilities | $1.9M | $3.1M | $22.7M | $20.3M | $16.5M | |
| Total Equity | $25.7M | $34.7M | $1M | $4M | $31.4M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$31.6M | -$31.3M | -$24.9M | -$5.1M | -$10.4M | |
| Cash From Investing | -- | -- | -- | -$15K | $13.3M | |
| Cash From Financing | $16.5M | $33M | $47.8M | -- | -$8.1M | |
| Free Cash Flow | -$31.6M | -$31.3M | -$24.9M | -$5.2M | -$10.4M | |
ACHV
Sector
Market Cap
$127.2M
$49.2M
Price % of 52-Week High
66.19%
48.57%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-11.27%
-30.94%
Beta (5-Year)
1.665
0.754
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$3.69
200-day SMA
Sell
Level
$4.63
Bollinger Bands (100)
Sell
Level
4.1 - 4.84
Chaikin Money Flow
Sell
Level
-391.9M
20-day SMA
Sell
Level
$3.99
Relative Strength Index (RSI14)
Sell
Level
35.69
ADX Line
Sell
Level
44.96
Williams %R
Neutral
Level
-64.3312
50-day SMA
Sell
Level
$4.34
MACD (12, 26)
Sell
Level
-0.22
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Neutral
Level
186.2M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
Stock Forecast FAQ
In the current month, ACHV has received 7 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ACHV average analyst price target in the past 3 months is $16.44.
-
Where Will Achieve Life Sciences Stock Be In 1 Year?
According to analysts, the consensus estimate is that Achieve Life Sciences share price will rise to $16.44 per share over the next 12 months.
-
What Do Analysts Say About Achieve Life Sciences?
Analysts are divided on their view about Achieve Life Sciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Achieve Life Sciences is a Sell and believe this share price will drop from its current level to $10.00.
-
What Is Achieve Life Sciences's Price Target?
The price target for Achieve Life Sciences over the next 1-year time period is forecast to be $16.44 according to 7 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ACHV A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Achieve Life Sciences is a Buy. 7 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ACHV?
You can purchase shares of Achieve Life Sciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Achieve Life Sciences shares.
-
What Is The Achieve Life Sciences Share Price Today?
Achieve Life Sciences was last trading at $3.68 per share. This represents the most recent stock quote for Achieve Life Sciences. Yesterday, Achieve Life Sciences closed at $3.70 per share.
-
How To Buy Achieve Life Sciences Stock Online?
In order to purchase Achieve Life Sciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
How High Can Palantir Stock Go?
Palantir Technologies (NASDAQ:PLTR) has been one of the undisputed victors…
Will This ETF Beat the Market Over the Next 12 Months?
2024 was another banner year for the US stock market,…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 121x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Sell
39
DOGZ alert for Jan 4
Dogness (International) [DOGZ] is down 20.52% over the past day.
Buy
66
DMRC alert for Jan 4
Digimarc [DMRC] is up 16.19% over the past day.
Sell
39
MSTR alert for Jan 4
MicroStrategy [MSTR] is up 13.33% over the past day.
